For certain hematologic malignancies, allogenenic hematopoietic stem cell transplantation (alloHCT) is a well-established therapy [1]. Initially alloHCT was used to strengthen the hematopoiesis after chemo-/radiotherapy, but nowadays the beneficial effects of graft-versus-leukemia (GvL) or graft-versus-tumor (GvT) is the main aim [2]. The beneficial effects are mediated by donor T cells recognizing patient-specific HLA-binding peptides. These peptides are called minor histocompatibility antigens (miHAs) and are typically caused by single nucleotide polymorphisms. Tissue-specific miHAs have successfully been used in anti-tumor therapy without causing unspecific graft-versus-host reactions. However, only a small number of miHAs have been identified to date, limiting the clinical use. There is thus a substantial need for fast and accurate identification of novel miHAs to enable immunotherapy for a large number of patients.